← Back to Clinical Trials
Recruiting NCT07697872

NCT07697872 The Dirty Nappy Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07697872
Status Recruiting
Phase —
Sponsor Birmingham Women's and Children's NHS Foundation Trust
Condition Cholestasis in Newborn
Study Type OBSERVATIONAL
Enrollment 5,350 participants
Start Date 2025-04-01
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 11 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,350 participants in total. It began in 2025-04-01 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This observational study evaluates whether a machine-learning algorithm, a computer program that learns patterns from data, can accurately diagnose cholestasis in newborns. Cholestasis refers to reduced or blocked bile flow from the liver, which can lead to liver damage. A severe form of cholestasis is biliary atresia, a condition where the bile ducts are damaged or absent, requiring early treatment to prevent long-term harm. The study involves infants from birth, both healthy and those potentially affected by cholestasis, recruited from four UK hospitals. It addresses two primary aims: * Accuracy of Diagnosis: Can the machine-learning algorithm accurately identify cholestasis and biliary atresia using parent-provided stool images? This will be assessed by measuring sensitivity (the ability to correctly detect true cases) and specificity (the ability to correctly identify infants without the condition). * Feasibility of Screening: Is using parent-provided images a feasible and acceptable screening method for early detection? To evaluate these aims, researchers will compare two groups: * Infants with abnormal stool images who are subsequently diagnosed with cholestasis or biliary atresia. * Infants with normal stool images who do not develop biliary atresia. This comparison will help determine the algorithm's ability to distinguish between infants with and without these conditions. Parents will: * Take smartphone photos of their baby's dirty diapers at 14, 21, and 28 days of age. * Upload the images for analysis by the algorithm. * Provide feedback on their experience with this screening process. The study seeks to determine if parent-submitted stool images can serve as a practical early screening tool for cholestasis, potentially enabling faster diagnosis and improved outcomes for affected infants.

Eligibility Criteria

Inclusion Criteria: All Arms: Informed Consent: Parents/guardians can give informed consent for their child's participation in the study and can understand written English. 1. Retrospective Cholestasis Arm: All infants, of any gestation, male and female who were referred to Birmingham Liver Unit from any hospital for investigation of suspected cholestasis within the previous 10 years before the study launch. At the time of the referral to Birmingham Liver Unit the children were under the age of 6 months and the children were referred before the start date of the study. 2. Prospective Cholestasis Arm: All infants, of any gestation, male and female who were referred to Birmingham Liver Unit from any hospital for investigation of suspected cholestasis after the study launch. At the time of the referral to Birmingham Liver Unit the children were under the age of 6 months. 3. Prospective Non-Cholestasis Arm All infants, of any gestation, male and female \& aged less than 28 days, not thought to be cholestatic at the time of recruitment \& with the birth registered at any of the participating hospital trusts. Exclusion Criteria: If the inclusion criteria as outlined are met, there is no exclusion criteria.

Frequently Asked Questions

Who can join the NCT07697872 clinical trial?

This trial is open to participants of all sexes, up to 11 Years, studying Cholestasis in Newborn. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07697872 currently recruiting?

Yes, NCT07697872 is actively recruiting participants. Visit ClinicalTrials.gov or contact Birmingham Women's and Children's NHS Foundation Trust to inquire about joining.

Where is the NCT07697872 trial being conducted?

This trial is being conducted at Birmingham, United Kingdom.

Who is sponsoring the NCT07697872 clinical trial?

NCT07697872 is sponsored by Birmingham Women's and Children's NHS Foundation Trust. The trial plans to enroll 5,350 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology